Raymond T. Chung
Experienced in Gastric Bypass

Dr. Raymond T. Chung

Hematology
1836 Noriega St, 
San Francisco, CA 
35 Years of Experience
Experienced in Gastric Bypass
1836 Noriega St, 
San Francisco, CA 
OverviewInsuranceLocationsClinical Research

Overview

Raymond Chung is a Hematologist in San Francisco, California. Dr. Chung has been practicing medicine for over 35 years and is rated as an Experienced provider by MediFind in Gastric Bypass. His top areas of expertise are Liver Failure, Cryoglobulinemia, Niemann-Pick Disease, and Gastric Bypass.

His clinical research consists of co-authoring 477 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Gastric Bypass.

Specialties
Hematology
Licenses
Pharmacist in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

1836 Noriega St, San Francisco, CA 94122

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Epclusa
Study Phase: Phase 2
B-Fine: An Open Label, Single Arm Study to Mechanistically Interrogate the Therapeutic Effect of GSK3228836 in Patients With Chronic Hepatitis B Via Intrahepatic Immunophenotyping
B-Fine: An Open Label, Single Arm Study to Mechanistically Interrogate the Therapeutic Effect of GSK3228836 in Patients With Chronic Hepatitis B Via Intrahepatic Immunophenotyping
Enrollment Status: Completed
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
HBV-HIV Coinfection Research Network
HBV-HIV Coinfection Research Network
Enrollment Status: Completed
Publish Date: May 16, 2023
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
Enrollment Status: Terminated
Publish Date: April 25, 2023
Intervention Type: Drug
Study Drug: Clinically Prescribed Direct Acting Antiviral (Mavyret or Epclusa) HCV Treatment for 12 Weeks
Study Phase: Phase 4
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19
Enrollment Status: Terminated
Publish Date: July 21, 2022
Intervention Type: Drug
Study Drug: PegIFN-Lambda Alpha1a
Study Phase: Phase 2
Safety, Efficacy, and Changes in Traditional and Novel Biomarkers of Kidney Function in Patients With Hepatitis C and Advanced Chronic Kidney Disease Treated With Abbvie Viekira Pak or Mavyret Regimen
Safety, Efficacy, and Changes in Traditional and Novel Biomarkers of Kidney Function in Patients With Hepatitis C and Advanced Chronic Kidney Disease Treated With Abbvie Viekira Pak or Mavyret Regimen
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Drugs: Viekira Pak ± Ribavirin, Mavyret
Study Phase: Phase 4
A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
Enrollment Status: Completed
Publish Date: June 09, 2020
Intervention Type: Drug
Study Phase: Phase 4
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers
Enrollment Status: Withdrawn
Publish Date: January 21, 2020
Intervention Type: Drug
Study Phase: Phase 4
Effect of Ledipasvir and Sofosbuvir on Proteinuria and Estimated Glomerular Filtration Rate in Patients With Early Stage (1-3) Hepatitis C Associated Chronic Kidney Disease
Effect of Ledipasvir and Sofosbuvir on Proteinuria and Estimated Glomerular Filtration Rate in Patients With Early Stage (1-3) Hepatitis C Associated Chronic Kidney Disease
Enrollment Status: Terminated
Publish Date: January 13, 2020
Intervention Type: Drug
Study Phase: Not Applicable
Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography
Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography
Enrollment Status: Completed
Publish Date: October 28, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 11 Less Clinical Trials

477 Total Publications

Automated, Deep Learning-Enabled Immunoassay Microfluidic Cartridge for Viral Pathogen Detection.
Automated, Deep Learning-Enabled Immunoassay Microfluidic Cartridge for Viral Pathogen Detection.
Journal: Advanced materials technologies
Published: October 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chung's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile